Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA Prosocial Effects and Familiarity
NCT05948683Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (4 arms), sponsored by University of Chicago. Primary endpoints: Natural Language Processing metrics and Facial expression analysis. Started Jul 2023; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05948683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948683.